Lonasen Effective in Adolescent Japanese Schizophrenia Patients: Sumitomo Dainippon

Sumitomo Dainippon Pharma said on July 22 that its atypical antipsychotic agent Lonasen (blonanserin) hit the primary endpoint in a PIII clinical study conducted in Japan for the treatment of adolescent patients with schizophrenia. In the study, 151 Japanese schizophrenia...read more